Bacterial Infection as an Adverse Effect of Telaprevir-based Triple Therapy for Chronic Hepatitis C Infection-Reference-Cited by-同舟云学术

Bacterial Infection as an Adverse Effect of Telaprevir-based Triple Therapy for Chronic Hepatitis C Infection

Published:2015 Issue:6 Volume:54 Page:567-572
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Kawano Akira¹,Ogawa Eiichi²,Furusyo Norihiro²,Nakamuta Makoto³,Kajiwara Eiji⁴,Dohmen Kazufumi⁵,Nomura Hideyuki⁶,Takahashi Kazuhiro⁷,Satoh Takeaki⁸,Azuma Koichi⁹,Tanabe Yuichi¹⁰,Shimoda Shinji¹¹,Kotoh Kazuhiro¹²,Hayashi Jun²,

Affiliation:

1. Department of Internal Medicine, Kitakyushu Municipal Medical Center, Japan

2. Department of General Internal Medicine, Kyushu University Hospital, Japan

3. Department of Gastroenterology, Kyushu Medical Center, National Hospital Organization, Japan

4. Department of Hepatology, Steel Memorial Yawata Hospital, Japan

5. Department of Internal Medicine, Chihaya Hospital, Japan

6. The Center for Liver Disease, Shin-Kokura Hospital, Japan

7. Department of Medicine, Hamanomachi Hospital, Japan

8. Center for Liver Disease, National Hospital Organization Kokura Medical Center, Japan

9. Department of Medicine, Kyushu Central Hospital, Japan

10. Department of Medicine, Fukuoka City Hospital, Japan

11. Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Japan

12. Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/54/6/54_54.3457/_pdf

Reference24 articles.

1. 1. Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 28: 1687-1695, 1998.

2. 2. Ogawa E, Furusyo N, Kajiwara E, et al. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study. J Hepatol 58: 495-501, 2013.

3. 3. Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 52: 833-844, 2010.

4. 4. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a Meta-analysis of observational studies. Ann Intern Med 158: 329-337, 2013.

5. 5. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965, 2001.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comorbilidad, medicación concomitante, uso de recursos y costes sanitarios asociados a los pacientes portadores del virus de la hepatitis C crónica en España;Gastroenterología y Hepatología;2018-04

2. Comorbidity, concomitant medication, use of resources and healthcare costs associated with chronic hepatitis C virus carriers in Spain;Gastroenterología y Hepatología (English Edition);2018-04

3. Antiviral Drugs;Side Effects of Drugs Annual;2016